drugset / Trial / NCT03046251

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

NCT03046251

Phase 4 Completed 30 enrolled State University of New York at Buffalo
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.

Timeline

Start
2015-08
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody 300 mg Intravenous

Indications